Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance

at or before the EASL meeting

and/or the Digestive Disease Week meeting. These meetings will take

place in April and May, respectively.

-- The company expects to initiate its 14-day triple combination study of

ITMN-191 in combination with Pegasys(R) and ribavirin, in the second

quarter of 2008. The study design and timeline will be shared at study


-- An Investigational New Drug (IND) application is expected to be filed

by Roche for ITMN-191/R7227 in the second half of 2008 to gain FDA

approval to study the compound in the United States.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2007, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 32601453. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 32601453. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (I

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Disease ... ANAHEIM, Calif., Oct. 20 In the ten months since ... Chagas, disease, some 241 blood donations in the United States ... cause,this serious and potentially fatal parasitic infection, according to data,released ...
... AACR Virtual Meeting -, LOS ANGELES, Oct. 19 ... that Kathleen Danenberg, the Company,s,President and Chief Executive Officer, ... tailoring medicine at the 2007 AACR-NCI-EORTC,International Conference on Molecular ... 2007 at the Moscone Convention Center,West in San Francisco. ...
... of Bristol-Myers Squibb, NEW YORK, Oct. 19 ... PMQCW) announced today that Chem Rx, a,major privately-owned ... will be presenting at the Paramount BioSciences Healthcare,Conference, ... in New York, NY. Steven Silva, Executive ...
Cached Biology Technology:Blood Donations in U.S. Testing Positive for Chagas' Disease 2Blood Donations in U.S. Testing Positive for Chagas' Disease 3Blood Donations in U.S. Testing Positive for Chagas' Disease 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3Chem Rx to Present at the Paramount BioSciences Healthcare Conference 2Chem Rx to Present at the Paramount BioSciences Healthcare Conference 3Chem Rx to Present at the Paramount BioSciences Healthcare Conference 4
(Date:4/15/2014)... and energy for nearly all life on Earth, yet ... example, little is known about how it is regulated ... we do not know the full list of the ... any organism. , , A type of single-cell green ... subject for photosynthesis research. Despite its importance in the ...
(Date:4/15/2014)... In a study of nearly 1,000 mother-child pairs, ... found that prenatal exposure to selective serotonin reuptake ... anxiety and other disorders, was associated with autism ... boys. The study, published in the online edition ... samples of ASD and DD cases, and population-based ...
(Date:4/15/2014)... If an insect drew a line as it ... a tangled mess. But there,s method to that mess, ... engineering and physics, who tries to find simple physical ... , It turns out the tiger beetle, ... reorientation dance as it chases its prey at blinding ...
Breaking Biology News(10 mins):Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2Photo: Tiger beetle's chase highlights mechanical law 2
... a unique facility in the US, researchers at the University of ... next step is to film how proteins work at molecular ... do in cells could be the key to cures for everything ... at the University of Gothenburg, and his research group were among ...
... in French . Researchers are watching as ... to predict the communities most likely to be hit by this ... alert the Canadians who may be at risk of picking up ... outdoors in spring and summer, when nymphal ticks are active but ...
... way to prevent a patient going blind but there ... transplantation is long. Scientists at the Sahlgrenska Academy at the ... cultivated stem cells on human corneas, which may in the ... 500 corneal transplantations are carried out each year in Sweden, ...
Cached Biology News:More effective method of imaging proteins 2Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada 2Stem cells can repair a damaged cornea 2
... strains are K-12 derivatives that have mutations ... glutathione reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielded ... host even though overall expression levels were ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Cy3 Ab Labeling Kit, 1 kit. ... CyDye fluorescent dyes. Conjugations are carried ... within 1 h. Dyes are packaged ... ensure consistent labelings. Category: Blotting & ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: